New England Journal of Medicine2021Open AccessHighly Cited

Once-Weekly Semaglutide in Adults with Overweight or Obesity

John Wilding, Rachel L. Batterham, Salvatore Calanna et al.

4,113 citations2021Open Access — see publisher for license terms1 related compound

Research Article — Peer-Reviewed Source

Original research published by Wilding et al. in New England Journal of Medicine. Redistributed under Open Access — see publisher for license terms. MedTech Research Group provides these references for informational purposes. We do not conduct original research. All studies are the work of their respective authors and institutions.

Abstract

In participants with overweight or obesity, 2.4 mg of semaglutide once weekly plus lifestyle intervention was associated with sustained, clinically relevant reduction in body weight. (Funded by Novo Nordisk; STEP 1 ClinicalTrials.gov number, NCT03548935).

Full Text

Full text is available at the publisher.

Read at Publisher
Article Details
DOI10.1056/nejmoa2032183
JournalNew England Journal of Medicine
Year2021
AuthorsJohn Wilding, Rachel L. Batterham, Salvatore Calanna, Melanie J. Davies, Luc F. Van Gaal, Ildiko Lingvay, Barbara McGowan, Julio Rosenstock, Marie Thi Dao Tran, Thomas A. Wadden, Sean Wharton, Koutaro Yokote, Niels Zeuthen, Robert F. Kushner
LicenseOpen Access — see publisher for license terms
Citations4,113